Emergen Research, a globally recognized provider of market intelligence and strategic business research, has released an in-depth analysis of the global Nuclear Imaging Market. The study provides comprehensive insights into market growth, emerging trends, technological developments, competitive dynamics, regional performance, and the factors influencing the adoption of nuclear imaging technologies across healthcare systems.
The global Nuclear Imaging Market was valued at USD 8.40 Billion in 2025 and is projected to grow from USD 9.15 Billion in 2026 to USD 19.80 Billion by 2035, registering a CAGR of 9.0% during the forecast period from 2026 to 2035. North America accounted for the largest revenue share of 42.7% in 2025, while Asia Pacific is expected to record the fastest growth during the forecast period.
Nuclear imaging combines advanced imaging equipment with radiopharmaceutical tracers to provide functional and molecular information that cannot always be obtained through conventional anatomical imaging. Increasing use of PET and SPECT technologies in oncology, cardiology, and neurology, along with advances in radiotracer development and scanner technologies, is creating new opportunities across the market.
Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-free-sample/220506
Nuclear Imaging Market Overview
Nuclear imaging plays an important role in modern diagnostic medicine by allowing physicians to observe physiological processes and molecular activity within the body. PET and SPECT systems work together with radiopharmaceutical tracers that emit detectable signals, enabling clinicians to identify abnormalities, evaluate disease progression, and monitor treatment response.
The market is evolving as radiopharmaceutical manufacturing networks become more consolidated and scanner technologies continue to improve. Since many nuclear imaging tracers have relatively short half-lives, reliable radiopharmacy networks and timely delivery are essential for ensuring that imaging facilities can perform procedures as scheduled.
The availability of new PET/CT systems with improved image quality and throughput is also contributing to market expansion. Equipment manufacturers are investing in advanced scanner technologies and image-processing capabilities to support more efficient diagnostic workflows.
Another important development is the expansion of radiotracers beyond established applications. PSMA-targeted imaging agents and other theranostic companion radiotracers are expanding the role of nuclear imaging in precision oncology, while research collaborations are supporting the development of quantitative PET biomarkers for more detailed assessment of treatment response.
Factors Driving Nuclear Imaging Market Growth
One of the key factors supporting the growth of the Nuclear Imaging Market is the expansion of radiopharmaceutical manufacturing and distribution capabilities. A PET or SPECT examination depends not only on the availability of imaging equipment but also on access to an appropriate radiotracer within the required timeframe.
The consolidation of radiopharmaceutical production networks is helping manufacturers expand their geographic reach and improve tracer availability. Siemens Healthineers consolidated its PET radiopharmaceutical operations under its Radiopharma business in November 2025, creating a network operating 60 facilities across nine countries and producing more than 100,000 batches of sterile PET radiopharmaceuticals annually.
Advances in PET/CT scanner technology are also supporting market development. Equipment manufacturers are introducing new systems and image-processing technologies designed to improve diagnostic throughput and image quality. GE HealthCare received U.S. FDA 510(k) clearance for its Aurora and Clarify DL technologies in May 2025, reflecting continued development of advanced nuclear imaging platforms.
The expansion of radiotracer approvals is another important growth factor. New tracers are allowing nuclear imaging to address a wider range of clinical needs, particularly in oncology. Lantheus Holdings received FDA approval for Tauklarify in January 2026, extending its radiopharmaceutical portfolio.
Academic and industry collaboration is also becoming increasingly important. Partnerships focused on quantitative PET biomarkers are supporting the development of more precise methods for measuring treatment response. GE HealthCare and Mayo Clinic expanded their collaboration in July 2026 around quantitative, biomarker-based PET measurement of treatment response.
Challenges and Restraints Affecting Market Growth
Despite increasing adoption, several factors can limit the expansion of the Nuclear Imaging Market. One of the most significant challenges is the high capital cost associated with PET/CT and SPECT/CT systems. Smaller hospitals and diagnostic facilities may face difficulties justifying these investments when procedure volumes are relatively low.
The concentration of radioisotope production is another concern. Because many nuclear imaging tracers have short half-lives, an interruption at a production facility can quickly affect the availability of radiopharmaceuticals across a geographic area.
Reimbursement policies also influence the economics of nuclear imaging procedures. Changes in radiopharmaceutical payment rates can affect the ability of hospitals and imaging centers to maintain profitable nuclear medicine services.
In addition, fluctuations in the cost of specialty isotopes and detector-grade materials can place pressure on equipment and radiopharmaceutical manufacturers. Supply-chain disruptions and international logistics uncertainty can further increase operational costs.
Competitive Landscape:-
The global Nuclear Imaging Market is moderately consolidated, with several established medical imaging and radiopharmaceutical companies accounting for a significant portion of market revenue. Companies are focusing on product development, strategic collaborations, mergers and acquisitions, radiopharmaceutical manufacturing expansion, and improvements in imaging technologies.
Major companies operating in the Nuclear Imaging Market include GE HealthCare Technologies Inc., Siemens Healthineers AG, Koninklijke Philips N.V., Canon Medical Systems Corporation, Lantheus Holdings, Inc., Curium Pharma, Bracco Imaging S.p.A., Cardinal Health, Inc., Jubilant DraxImage Inc., and Blue Earth Diagnostics Ltd.
Competition is increasingly influenced by the integration of scanner hardware, imaging software, radiopharmaceutical availability, and diagnostic capabilities. Companies with broader capabilities across these areas are working to strengthen their positions as demand for advanced nuclear imaging procedures increases.
Market Segmentation:-
The global Nuclear Imaging Market is segmented on the basis of product, modality, application, end user, and region. These categories reflect differences in imaging equipment, diagnostic technologies, clinical applications, healthcare settings, and geographic demand.
By product, the market is divided into Imaging Equipment and Radiopharmaceuticals & Imaging Agents. Imaging Equipment accounted for the largest share of 56.4% in 2025. This segment includes PET, SPECT, and hybrid PET/CT and SPECT/CT systems used for diagnostic imaging.
The Radiopharmaceuticals & Imaging Agents segment is expected to expand at a CAGR of 11.4% through 2035. Growth is supported by expanding radiopharmacy production capacity and the development of new diagnostic tracers. Unlike imaging equipment, radiopharmaceuticals are consumed during individual procedures, making their demand closely connected to nuclear imaging procedure volumes.
By modality, the market is segmented into PET and SPECT. PET held the largest share of 51.8% in 2025 and is expected to register a CAGR of 10.6% through 2035. PET is widely used in oncology for cancer staging and treatment-response assessment and is also applied in cardiology and neurology.
SPECT remains an important nuclear imaging modality, particularly for cardiology and general nuclear medicine applications. Its established installed base and relatively lower capital requirements compared with PET and hybrid PET/CT systems support continued adoption.
By application, Oncology accounted for the largest share of 48.6% in 2025 and is expected to grow at a CAGR of 11.8% through 2035. Nuclear imaging is extensively used for cancer diagnosis, staging, treatment planning, and monitoring of treatment response. PSMA-targeted imaging for prostate cancer is one of the major applications supporting oncology demand.
Cardiology and neurology represent additional important application areas. Cardiac nuclear imaging is used for myocardial perfusion and viability assessment, while neurological applications include imaging for dementia and epilepsy evaluation.
By end user, Hospitals held the largest share of 54.3% in 2025. Hospitals typically operate nuclear imaging services alongside oncology, cardiology, and neurology departments, making them important centers for complex diagnostic procedures.
Diagnostic imaging centers are also expected to experience significant growth, with the segment projected to register a CAGR of 10.9% through 2035. Increasing movement toward outpatient imaging is supporting the expansion of dedicated diagnostic facilities.
Custom Requirements can be requested for this Report [Customization Available] @ https://www.emergenresearch.com/request-for-customization/220506
Businesses, healthcare organizations, investors, and other stakeholders can request customized analysis covering specific products, modalities, applications, regions, or competitive requirements. Customized research can help organizations evaluate market opportunities and develop strategies aligned with their specific business objectives.
Value Chain Analysis
The Nuclear Imaging Market value chain begins with isotope production and radiopharmaceutical manufacturing and extends through imaging equipment manufacturing, distribution, healthcare facilities, and patient diagnosis.
Radiopharmacies and isotope producers manufacture and distribute short-lived tracers that must reach hospitals and imaging centers within strict timeframes. The availability of these tracers directly affects the utilization of PET and SPECT equipment.
Equipment manufacturers such as GE HealthCare, Siemens Healthineers, Philips, and Canon Medical design and manufacture PET and SPECT imaging systems. While scanner hardware and radiopharmaceuticals represent separate supply chains, they must operate in coordination because imaging equipment requires an appropriate tracer to perform a nuclear imaging procedure.
Hospitals and diagnostic imaging centers represent the final stage of the value chain, where imaging procedures are performed and the resulting information is used by physicians for diagnosis, treatment planning, and treatment monitoring.
Regulatory Landscape
Nuclear imaging equipment in the United States is generally subject to FDA regulatory requirements, including the 510(k) clearance pathway for applicable imaging devices. Under this pathway, manufacturers demonstrate that a new device is substantially equivalent to a legally marketed predicate device.
Radiopharmaceutical imaging agents are regulated as drugs and require appropriate FDA approval demonstrating safety and diagnostic effectiveness. Regulatory approval for imaging agents therefore follows a different pathway from the clearance process applicable to many imaging devices.
Reimbursement represents another important regulatory and commercial consideration. The Centers for Medicare & Medicaid Services has implemented adjustments to radiopharmaceutical payment policies, affecting how imaging agents are reimbursed in relation to nuclear medicine procedures.
Nuclear Imaging Market Regional Insights
North America accounted for 42.7% of the global Nuclear Imaging Market in 2025, making it the largest regional market. The region benefits from established radiopharmacy distribution networks, leading imaging and radiopharmaceutical companies, advanced healthcare infrastructure, and developed reimbursement systems.
The United States led the North American market in 2025. The presence of major companies such as GE HealthCare, Lantheus Holdings, and Siemens Healthineers supports the region's strong position across both imaging equipment and radiopharmaceutical supply.
Europe represented approximately 26.8% of the global market in 2025. The region has an established radiopharmaceutical manufacturing base and mature nuclear medicine infrastructure. Continued investment in advanced imaging technologies and radiopharmacy capabilities is supporting market development.
Asia Pacific is expected to be the fastest-growing regional market, with a projected CAGR of 12.1% through 2035. Increasing installation of PET and SPECT systems, expanding oncology diagnosis, and growing healthcare investment are contributing to demand. China led the Asia Pacific market in 2025.
Latin America is projected to grow at a CAGR of 8.7% through 2035. Market development is being supported by increasing access to PET and SPECT imaging, particularly among larger hospital networks and specialized healthcare facilities.
The Middle East & Africa market is projected to grow at a CAGR of 8.3% through 2035. Continued investment in oncology and cardiology imaging infrastructure, particularly across leading academic and specialty medical centers, is expected to support regional growth.
Recent Industry Developments
In November 2025, Siemens Healthineers consolidated its PET radiopharmaceutical businesses PETNET Solutions and Advanced Accelerator Applications Molecular Imaging under the Siemens Healthineers brand. The consolidation created a single Radiopharma segment operating 60 facilities across nine countries.
In May 2025, GE HealthCare received U.S. FDA 510(k) clearance for its Aurora and Clarify DL technologies. The clearance expanded the company's imaging and image-processing capabilities and reflected continued investment in advanced imaging software and diagnostic technologies.
In January 2026, Lantheus Holdings received U.S. FDA approval for Tauklarify, expanding its oncology-focused radiopharmaceutical portfolio and strengthening its position in diagnostic imaging agents for cancer detection and staging.
Future Outlook for the Nuclear Imaging Market
The Nuclear Imaging Market is expected to continue expanding as healthcare providers increasingly adopt PET and SPECT technologies for molecular and functional diagnosis. Improvements in scanner performance, radiopharmaceutical availability, and targeted radiotracer development are expected to remain important contributors to market growth.
The market is projected to reach USD 19.80 Billion by 2035 from USD 8.40 Billion in 2025, representing a CAGR of 9.0% during 2026–2035. Oncology is expected to remain a major application area, while increasing adoption of nuclear imaging in cardiology and neurology will create additional opportunities.
The continued development of radiopharmacy networks, new radiotracers, quantitative PET biomarkers, and advanced imaging platforms is expected to shape the industry's long-term growth. At the same time, manufacturers and healthcare providers will need to address equipment costs, tracer supply-chain concentration, reimbursement conditions, and material cost volatility.
Browse Full Report Description + Research Methodology + Table of Content + Infographics @ https://www.emergenresearch.com/industry-report/nuclear-imaging-market
About Emergen Research
Emergen Research is a market research and consulting company providing data-driven insights across multiple industries. The company offers market intelligence, competitive analysis, strategic research, and customized consulting solutions to help organizations understand changing market dynamics and identify emerging business opportunities.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: https://www.emergenresearch.com/
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com